A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies.

Al-Samkari, Hanny; Eng, Whitney

Al-Samkari, Hanny; Eng, Whitney.

Affiliation

Al-Samkari H; Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Eng W; Harvard Medical School, Boston, Massachusetts, USA.

J Thromb Haemost ; 20(5): 1077-1088, 2022 05.

Article in En | MEDLINE | ID: mdl-35343049

Subject(s)

Telangiectasia, Hereditary Hemorrhagic; Vascular Malformations; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Precision Medicine; Telangiectasia, Hereditary Hemorrhagic/diagnosis; Telangiectasia, Hereditary Hemorrhagic/drug therapy; Telangiectasia, Hereditary Hemorrhagic/genetics; Vascular Endothelial Growth Factor A; Vascular Malformations/diagnosis; Vascular Malformations/genetics; Vascular Malformations/therapy

Key words

alpelisib; bevacizumab; hereditary hemorrhagic telangiectasia; pazopanib; trametinib; vascular anomalies

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Telangiectasia, Hereditary Hemorrhagic / Vascular Malformations Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2022 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google